Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2013

Boland Jennifer M, Jang Jin Sung, Li Jun, Lee Adam M, Wampfler Jason A, Erickson-Johnson Michele R, Soares Ibere, Yang Ping, Jen Jin, Oliveira Andre M, Yi Eunhee S

Abstract excerpt

INTRODUCTION: Oncogenic ALK kinase activity associated with ALK gene rearrangement is the target of crizotinib, an ALK inhibitor recently approved by the Food and Drug Administration for the treatment of ALK-rearranged (ALK+) non-small cell lung cancers. ALK+ status is generally thought to be mutually exclusive of epidermal growth factor receptor (EGFR) and KRAS mutations. However, the mutation status of other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Oligonucleotide Array Sequence Analysis

Share to Oncogene Proteins, Fusion

Share to Proto-Oncogene Proteins c-met

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 23449277
DOI: 10.1097/JTO.0b013e318287c395

Genes

ALK
MET
EGFR
KRAS
AKT1
AKT2
BRAF
ERBB2
JAK2
KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases.PMID 23449277Read ↗

ALK in lung cancer: past, present, and future.Semantic proximity Read ↗

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.Semantic proximity Read ↗

Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.Semantic proximity Read ↗

A Pan-Cancer Review of ALK Mutations: Implications for Carcinogenesis and Therapy.Semantic proximity Read ↗

ALK‐ rearrangement in non‐small‐cell lung cancer (NSCLC)Semantic proximity Read ↗

Targeting oncogenic ALK: a promising strategy for cancer treatment.Semantic proximity Read ↗

The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.Semantic proximity Read ↗

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.Semantic proximity Read ↗

Novel mutations in a patient with ALK-rearranged lung cancer.Semantic proximity Read ↗

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancerSemantic proximity Read ↗

ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.Semantic proximity Read ↗

ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.